DBVT logo

DBV Technologies S.A. (DBVT)

$9.99

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DBVT

Market cap

$628148832

EPS

-0.61

P/E ratio

--

Price to sales

115.64

Dividend yield

--

Beta

-0.842955

Price on DBVT

Previous close

$10.27

Today's open

$10.20

Day's range

$9.79 - $10.22

52 week range

$8.63 - $26.19

Profile about DBVT

CEO

Daniel Tass

Employees

125

Headquarters

Chtillon,

Exchange

NASDAQ Capital Market

Shares outstanding

62877761

Issue type

American Depository Receipt

DBVT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on DBVT

DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears

DBV Technologies NASDAQ: DBVT is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics license application, executives said at Guggenheim's Healthcare Innovation Conference.

news source

MarketBeat • Nov 9, 2026

news preview

DBV Technologies: Down 55% Since April, Yet My $42 Fair Value Still Holds

DBV Technologies is rated Speculative Strong Buy with a $42 per ADS fair value, despite recent sector- and company-specific share price declines. My revised DCF incorporates higher discount rates, regulatory delay probabilities, and dilution but still indicates attractive risk/reward at approximately $10 per ADS. Key risks include regulatory delays, manufacturing issues at Fareva Amboise, and management credibility concerns, with a total investment loss remaining possible.

news source

Seeking Alpha • Nov 7, 2026

news preview

DBV Technologies to Participate in Upcoming November Investor Conferences

Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in November: Guggenheim Securities 3rd Annual Healthcare Innovation Conference – November 9, 2026 Format: Fireside ChatTime:  8:00 am ETLocation: Boston, MA 2026 LifeSci Growth & Innovation Summit – November 16, 2026 Format: 1 on 1 MeetingsLocation: London, UK A live webcast of the fireside chat will be available on the Events section of the Company's website here. Replays will also be available on DBV Technologies' website for 90 days after the event.

news source

GlobeNewsWire • Nov 2, 2026

news preview

What DBV Technologies (DBVT) Said on Its Q3 Earnings Call

DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing preparations for a potential commercial launch and addressing manufacturing readiness at its contract manufacturing partner.

news source

MarketBeat • Oct 29, 2026

news preview

DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript

DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 29, 2026

news preview

DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update

Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children aged 4-7 Years and requested Priority Review Accelerated Commercial Readiness towards the launch of the VIASKIN® Peanut Patch in children aged 4-7 years in the US, if approved Reported cash and cash equivalents of $165.7 million as of September 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, October 28, at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage specialty biopharmaceutical company, today reported financial results for the Third Quarter of 2026. The quarterly and nine months financial statements were approved by the Board of Directors on October 28, 2026.

news source

GlobeNewsWire • Oct 28, 2026

news preview

DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026

Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Wednesday, October 28th, at 5:00 p.m. ET to review its third quarter 2026 financial results and provide a business update.

news source

GlobeNewsWire • Oct 27, 2026

news preview

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population.  DBV has requested Priority Review of the BLA.

news source

GlobeNewsWire • Sep 29, 2026

news preview

DBV Technologies to Participate in Upcoming September Investor Conferences

Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September: 2026 Cantor Global Healthcare Conference – September 9, 2026 Format:         Fireside Chat Time:            1:00pm ETLocation:       New York, NY Citi's 2026 Biopharma Back to School Conference – September 10, 2026 Format:         1 on 1 MeetingsLocation:       New York, NY H.C. Wainwright 28 th Annual Global Investment Conference – September 15, 2026 Format:         Fireside ChatTime:            3:00pm ETLocation:      New York, NY Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.

news source

GlobeNewsWire • Sep 3, 2026

news preview

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

Information Regarding the Total Number of Voting Rights and  Total Number of Shares of the Company as of August 31, 2026

news source

GlobeNewsWire • Sep 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in DBV Technologies S.A.

Open an M1 investment account to buy and sell DBV Technologies S.A. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DBVT on M1